Nanobac Life Sciences, Inc. Announces Nanobacteria Can Cause Kidney Stones.

TAMPA, Fla. -- Nanobac Life Sciences, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced the publication of "Lithogenesis: induction of renal calcifications by nanobacteria" by Shiekh, et. al. in Urological Research (Volume 34, Number 1, Pages 53-57, 2006). As part of their experiments, rats were injected with nanobacteria. After 8 weeks the kidneys were found to have chronic inflammation and nanobacterial calcified kidney stones. These results confirm previous findings by Cuerpo, et al. that nanobacteria cause kidney stones. Inflammation is often seen at sites of abnormal calcification and in these experiments nanobacteria are found to be the link between inflammation and calcification.

"About 1 million Americans have kidney stones each year and half of those people will suffer from recurrent kidney stones," said John Stanton, Nanobac's Chairman and CEO. "There is a tremendous need for preventative medicine. Knowing that nanobacteria, also known as Calcifying Nano-Particles (CNPs), might be one of the causes of kidney stones allows us to focus our efforts on future treatments and diagnostic tests. That is why we are excited about the collaborative kidney research currently underway with NASA, Mission Pharmacal and University of California San Francisco."

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is a broad-based life science company that discovers, develops, manufactures, and markets a range of products and services to improve people's health through the detection and treatment of Calcifying Nano-Particles, otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for the detection of Calcifying Nano-Particles. IVD products include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM) line of antibodies and reagents. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac's Drug Discovery and Development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.